FindTrial
Sign In

Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT07119775
Enrollment
Unknown
Registered
2025-08-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Myotonic Dystrophy

Keywords

Tideglusib, Congenital Myotonic Dystrophy, Myotonic Dystrophy, Dystrophia Myotonica, Myotonia Atrophica, Myotonia Dystrophica, Myotonic Dystrophy, Congenital Steinert Disease, Steinert Myotonic Dystrophy, Steinert's Disease

Brief summary

This treatment plan is limited to a single patient with Congenital Myotonic Dystrophy, who is ineligible or otherwise unable to participate in ongoing clinical trials.

Interventions

DRUGTideglusib

Sponsors

AMO Pharma Limited
Lead SponsorINDUSTRY

Eligibility

Contacts

Primary ContactHarriet Gray-Stephens, BM BCh, MA (Oxon), MFPM
h.graystephens@amo-pharma.com+44 (0)1270 270010

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026